Key Points
  • Pharma companies strive to achieve competitive advantage by making profitable investments in different therapeutic areas

  • One particular area of potential investment is cancer treatment

  • WNS conducted a research- and analytics-led therapy area analysis, through which it identified treatment gaps and the molecules available as potential investment opportunities

  • WNS’ study enables pharmaceutical companies to drive growth with informed investment decisions in drug research

The Market Situation

In the face of stiff competition, global bio-pharmaceutical companies are on the lookout for profitable investments in different therapeutic areas. One particular area of potential investment is cancer treatment using a class of promising drugs – the Programmed Cell Death Protein 1 (PD-1) Inhibitors. To identify investment opportunities in this therapeutic area, pharmaceutical companies require an in-depth analysis of cancer treatment using PD-1 inhibitors, and a timely review of the competitive landscape.

The WNS Solution

Against this industry backdrop, WNS — a market leader in offering competitive intelligence and analytics for the pharmaceutical industry — leveraged its vast resources of professionals such as chemists, pharmacists, doctors, pharma marketers and analysts, to conduct an in-depth, research-based, therapy area analysis for cancer treatment using PD-1 inhibitors.

This comprehensive analysis comprises:

  • Disease pathophysiology (Functional changes associated with the type of cancer)

  • Disease etiology (Causes and origin of the type of cancer)

  • Use of PD-1 inhibitors in cancer development and progress

  • Identification of the available treatment options for the disease

  • Pipeline analysis to identify the drugs that make up the competitive landscape 

The analysis is supplemented with pipeline analysis, which helps identify drugs that constitute the competitive landscape. 

Expected Outcomes:

WNS' therapy area analysis provides pharmaceutical companies critical insights such as:

  • Treatment gaps in cancer treatment using PD-1 inhibitors

  • PD-1 inhibitor molecules that are available as potential investment opportunities 


Get more information about WNS’ Pharmaceutical Healthcare Outsourcing Solutions or contact us with questions.

Reach Out To Us ENQUIRE NOW
Follow us on:
Stay Updated